Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

Cantargia: ASCO conference was the Q2 pinnacle - Nordea

Cantargia

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Cantargia's Q2 report offered few surprises. In our view, the main highlight of the quarter was the ASCO conference, where the company revealed positive interim data for its lead candidate, CAN04. We view this as a positive addition to Cantargia's data package, which is favourable for future partnership negotiations. There is a potential negative read-across for IL-1 inhibitors in oncology due to another failed study in the Novartis CANOPY programme (this time in the adjuvant setting), but we believe that each drug targeting IL-1 biology should stand on its own merits. Marketing material commissioned by Cantargia.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.